# A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

> **NCT03230292** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 43 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT03230292
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-03
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-03-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230292, "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03230292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*